| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total other income (expense), net | -41,283 | -47,380 | 27,496 | |
| Loss before income taxes | -186,482 | -181,658 | - | |
| Provision for (benefit from) income taxes | -1,545 | 2,100 | - | |
| Net loss | -184,937 | -183,758 | -164,254 | |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -2,194 | -1,855 | -2,214 | |
| Net loss attributable to common stockholders of bridgebio | -182,743 | -181,903 | -162,040 | |
| Net loss per share attributable to common stockholders of bridgebio, basic (in dollars per share) | -0.95 | -0.95 | -0.86 | |
| Net loss per share attributable to common stockholders of bridgebio, diluted (in dollars per share) | -0.95 | -0.95 | -0.86 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, basic (in shares) | 191,854,152 | 190,517,215 | 188,510,372 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, diluted (in shares) | 191,854,152 | 190,517,215 | 188,510,372 | |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)